Pressure BioSciences (OTCQB: PBIO) today announced that a Centre
for the Proteome of Human Cancer (“ProCan”) scientific team has published a
recommended sample preparation protocol built around PBIO’s Barocycler
instrument system, which is designed to improve diagnosis and treatment of
cancers through optimizing the identification and use of novel biomarkers. Per
the update, ProCan scientists have named the new protocol Accelerated
Barocycler Lysis and Extraction (“ABLE”), which is based on PBIO’s proprietary
pressure cycling technology (“PCT”) platform for the rapid breakup of tissue
samples and release of molecules for analysis. “We are pleased that ProCan has
developed an advanced sample processing system, featuring the use of our
Barocycler instrument system,” PBIO Senior VP and Chief Commercial Officer Dr.
Bradford Young stated in the news release. “The ABLE method will enable
scientists worldwide to benefit from the advantages of our PCT platform
technology for cancer profiling and drug development, as reported by ProCan
scientists and their colleagues. We believe the ABLE method has the potential
to help transform the way cancer is diagnosed and treated for improved patient
outcomes.”
To view the full press release, visit http://ibn.fm/q1l2H
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics characterization
and quality control, soil & plant biology, forensics, and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of its pressure-based technologies in the following areas: (1) the use of
its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into
the biologics contract research services sector, and (2) the use of its
recently-patented, scalable, high-efficiency, pressure-based Ultra Shear
Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise
immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality,
homogenized, extended shelf-life or room temperature stable low-acid liquid
foods that cannot be effectively preserved using existing non-thermal technologies.
For more information, visit the company’s website at www.PressureBiosciences.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
